Ibetin (Ibuprofen)

What Is Ibetin and What Is It Used For?

Ibetin is a brand-name medicine containing ibuprofen 200 mg as a film-coated tablet. It belongs to the NSAID (non-steroidal anti-inflammatory drug) class and is used to treat pain, inflammation, and fever associated with a wide range of conditions including arthritis, headache, dental pain, menstrual cramps, and musculoskeletal injuries.

Ibuprofen, the active substance in Ibetin, is one of the most commonly used medicines worldwide and has been included on the World Health Organization (WHO) Model List of Essential Medicines since its inception. It was first developed in the 1960s and has since accumulated decades of clinical evidence supporting its efficacy and safety profile when used appropriately.

Ibetin works by inhibiting both cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) enzymes. These enzymes are responsible for the production of prostaglandins, thromboxanes, and prostacyclin – lipid compounds that play key roles in mediating pain, inflammation, and fever. By reducing prostaglandin synthesis, Ibetin provides analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) effects.

The main indications for Ibetin include:

• Osteoarthritis – pain, stiffness, and swelling in degenerative joint disease
• Rheumatoid arthritis – chronic inflammatory joint disease
• Ankylosing spondylitis – inflammatory disease of the spine
• Mild to moderate pain – headache, toothache, backache, muscle aches, and menstrual pain (dysmenorrhea)
• Fever – reduction of elevated body temperature in adults and children
• Post-operative and post-traumatic pain – following surgical procedures or injuries
• Gouty arthritis – acute gout flares

After oral administration, ibuprofen is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations typically reached within 1 to 2 hours. The drug is highly protein-bound (greater than 99%) and is metabolized primarily in the liver by the cytochrome P450 enzyme CYP2C9. The elimination half-life is approximately 2 to 4 hours, which is why dosing is typically required every 4 to 6 hours for pain relief.

What Should You Know Before Taking Ibetin?

Before taking Ibetin, it is essential to inform your doctor about any existing medical conditions, allergies, current medications, and whether you are pregnant or breastfeeding. Certain conditions and drug combinations significantly increase the risk of serious side effects.

Contraindications

Ibetin must not be taken in the following situations:

• Known allergy to ibuprofen or other NSAIDs: Patients who have experienced asthma, urticaria (hives), or allergic-type reactions after taking aspirin or other NSAIDs should not take Ibetin. Cross-reactivity between NSAIDs is well-documented and can trigger severe bronchospasm or anaphylaxis.
• Active gastrointestinal bleeding or ulceration: Ibetin inhibits COX-1, which normally produces protective prostaglandins in the stomach lining. Taking Ibetin with existing ulcers or bleeding can worsen these conditions significantly.
• Severe heart failure (NYHA Class IV): NSAIDs cause sodium and fluid retention, which can exacerbate heart failure symptoms and increase hospitalization risk.
• Severe hepatic or renal impairment: Ibuprofen is metabolized by the liver and can reduce renal blood flow, potentially worsening pre-existing liver or kidney disease.
• Third trimester of pregnancy: Ibetin is contraindicated from week 20 of pregnancy onwards due to the risk of premature closure of the fetal ductus arteriosus and impaired fetal renal function.
• Perioperative setting of coronary artery bypass surgery (CABG): NSAIDs are associated with increased cardiovascular thrombotic events in this clinical context.

Warnings and Precautions

Special caution is warranted in patients with the following conditions or risk factors:

• Cardiovascular disease or risk factors: NSAIDs may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. This risk may increase with duration of use and is greater in patients with established cardiovascular disease. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) both require boxed warnings regarding this risk.
• History of gastrointestinal problems: Patients with a history of peptic ulcers, GI bleeding, or inflammatory bowel disease (Crohn's disease, ulcerative colitis) should use Ibetin with extreme caution. Concurrent use of a proton pump inhibitor (PPI) may be recommended for gastroprotection.
• Hypertension: Ibuprofen can elevate blood pressure and may interfere with the effectiveness of antihypertensive medications. Regular blood pressure monitoring is recommended during treatment.
• Elderly patients (over 65 years): Older adults are at higher risk for all NSAID-related adverse effects, including GI bleeding, cardiovascular events, and renal impairment. The lowest effective dose should be used.
• Asthma: Approximately 10-20% of adults with asthma have aspirin-sensitive asthma, and cross-reactivity with other NSAIDs including ibuprofen is common. Ibetin may precipitate bronchospasm in these patients.
• Coagulation disorders: Ibuprofen inhibits platelet aggregation and may prolong bleeding time, which is relevant for patients with bleeding disorders or those on anticoagulant therapy.

Pregnancy and Breastfeeding

The use of Ibetin during pregnancy requires careful consideration at each stage:

• First trimester (weeks 1-12): Some observational studies suggest a possible association between NSAID use in early pregnancy and an increased risk of miscarriage and certain congenital malformations, particularly cardiac defects. Use should be avoided unless clearly necessary and after discussing risks with a physician.
• Second trimester (weeks 13-19): Use only if the potential benefit justifies the potential risk to the fetus. The lowest effective dose for the shortest duration should be employed.
• From week 20 onwards: Ibetin is contraindicated. NSAIDs can cause oligohydramnios (reduced amniotic fluid) due to fetal renal dysfunction, and in the third trimester, there is a well-established risk of premature closure of the ductus arteriosus. These effects can occur even after short-term use.
• Breastfeeding: Ibuprofen is excreted in breast milk in very small quantities. Due to its short half-life and low milk transfer, it is generally considered compatible with breastfeeding at standard analgesic doses. However, consulting a healthcare provider before use is recommended.

How Does Ibetin Interact with Other Drugs?

Ibetin (ibuprofen) has clinically significant interactions with several commonly used medications. The most important interactions involve anticoagulants, other NSAIDs, aspirin, lithium, methotrexate, and drugs that affect kidney function. Always inform your doctor and pharmacist about all medications you are taking.

Drug interactions with ibuprofen occur through several pharmacological mechanisms: competition for protein binding, effects on renal prostaglandin synthesis, alterations in drug metabolism, and additive pharmacological effects. Understanding these interactions is crucial for safe medication use.

Major Interactions

Other Important Interactions

What Is the Correct Dosage of Ibetin?

The dosage of Ibetin depends on the condition being treated, the patient's age, and individual risk factors. The general principle is to use the lowest effective dose for the shortest duration necessary. For adults, typical analgesic doses range from 200-400 mg every 4-6 hours, with a maximum of 1,200 mg per day for self-treatment or up to 2,400 mg per day under medical supervision.

Ibetin 200 mg film-coated tablets should be swallowed whole with a glass of water. They should not be crushed, broken, or chewed. Taking Ibetin with food or milk may help reduce gastrointestinal discomfort, although this may slightly delay the onset of action.

Adults

Children

Ibetin 200 mg film-coated tablets are generally not recommended for young children due to the tablet form. For children over 12 years weighing more than 40 kg, the adult dose may be used under medical guidance. For younger children, liquid ibuprofen formulations are more appropriate and allow weight-based dosing (typically 5-10 mg/kg per dose every 6-8 hours, maximum 3-4 doses in 24 hours).

Elderly Patients

Elderly patients (over 65 years) are at significantly higher risk for NSAID-related adverse effects. The British National Formulary (BNF) and EMA recommend starting with the lowest effective dose and using Ibetin for the shortest duration necessary. Renal function should be monitored regularly, as age-related decline in kidney function can reduce ibuprofen clearance and increase the risk of accumulation and toxicity.

Missed Dose

If you miss a dose of Ibetin and are taking it on a regular schedule, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. When using Ibetin on an as-needed basis for pain, simply take the next dose when pain returns, ensuring you do not exceed the maximum daily dose.

Overdose

In the event of an overdose, seek immediate medical attention or contact a poison control center. Symptoms of ibuprofen overdose may include nausea, vomiting, epigastric pain, drowsiness, dizziness, headache, tinnitus (ringing in the ears), and in more severe cases, gastrointestinal bleeding, metabolic acidosis, seizures, hypotension, and acute renal failure. There is no specific antidote for ibuprofen overdose; treatment is supportive and symptomatic.

What Are the Side Effects of Ibetin?

Like all NSAIDs, Ibetin can cause side effects, although not everybody gets them. The most common side effects are gastrointestinal in nature, including nausea, dyspepsia, and abdominal pain. Serious but less common side effects include gastrointestinal bleeding, cardiovascular events, and kidney problems. The risk of side effects increases with higher doses and longer duration of treatment.

The side effect profile of ibuprofen has been extensively studied in both clinical trials and post-marketing surveillance involving millions of patients worldwide. Understanding the frequency and nature of potential adverse effects helps patients and healthcare providers make informed treatment decisions. Side effects are classified below according to the internationally standardized frequency categories used by the EMA.

The risk of cardiovascular side effects has been the subject of extensive research. A landmark 2013 meta-analysis published in The Lancet by the Coxib and Traditional NSAID Trialists' (CNT) Collaboration found that high-dose ibuprofen (2,400 mg/day) was associated with a moderately increased risk of major vascular events, similar in magnitude to that seen with COX-2 selective inhibitors. However, at lower doses commonly used for pain relief (up to 1,200 mg/day), the cardiovascular risk appears to be lower.

Gastrointestinal side effects remain the most clinically important concern with NSAID use. The risk of GI complications is dose-dependent and increases with duration of treatment, age over 65, history of peptic ulcer disease, concurrent use of corticosteroids or anticoagulants, and the presence of Helicobacter pylori infection. Co-prescription of a proton pump inhibitor (PPI) is recommended for patients at elevated GI risk who require NSAID therapy.

How Should You Store Ibetin?

Store Ibetin at room temperature (below 25°C / 77°F) in the original packaging to protect from light and moisture. Keep out of the reach and sight of children. Do not use after the expiry date printed on the packaging.

Proper storage of medicines is essential to maintain their efficacy and safety throughout the shelf life. Ibetin film-coated tablets should be kept in their original blister packaging until use to protect them from environmental factors that could affect their stability.

Specific storage guidelines for Ibetin include:

• Temperature: Store at room temperature, below 25°C (77°F). Do not refrigerate or freeze.
• Moisture: Keep the tablets in their original blister packaging to protect from humidity. Do not store in bathrooms or other areas with high humidity.
• Light: Protect from direct sunlight by keeping in original packaging.
• Children: Store in a location that is out of the reach and sight of children. Consider using a lockable medicine cabinet.
• Expiry date: Do not use Ibetin after the expiry date stated on the packaging. The expiry date refers to the last day of that month.
• Disposal: Do not dispose of medicines via household waste or wastewater. Return unused or expired medicines to a pharmacy for proper disposal in accordance with local environmental regulations.

If you notice any visible changes to the tablets such as discoloration, crumbling, or an unusual odor, do not take them. Consult your pharmacist for advice and obtain a new supply.

What Does Ibetin Contain?

Each Ibetin film-coated tablet contains 200 mg of ibuprofen as the active ingredient. The tablets also contain several inactive ingredients (excipients) that serve as fillers, binders, and coating agents necessary for the manufacturing and stability of the tablet.

The active substance in Ibetin is ibuprofen (International Nonproprietary Name, INN). Ibuprofen is a racemic mixture of the R(-) and S(+) enantiomers. The S(+) enantiomer is the pharmacologically active form responsible for COX inhibition. After oral administration, approximately 60% of the R(-) form is slowly converted to the active S(+) enantiomer in the body.

Typical excipients in ibuprofen film-coated tablets include:

• Microcrystalline cellulose – a filler and binder that provides the tablet with structural integrity
• Croscarmellose sodium – a disintegrant that helps the tablet break apart in the gastrointestinal tract for proper absorption
• Colloidal silicon dioxide – a glidant that ensures uniform tablet formation during manufacturing
• Magnesium stearate – a lubricant that prevents the tablet from sticking to manufacturing equipment
• Hypromellose – a component of the film coating that protects the tablet and facilitates swallowing
• Titanium dioxide (E171) – a white pigment used in the film coating
• Iron oxide yellow (E172) – a coloring agent giving the tablet its light yellow to beige appearance

Ibetin tablets are described as light yellow to beige, round, film-coated tablets with a diameter of approximately 9 mm. They are available in blister packs, typically in pack sizes of 20, 30, 50, or 100 tablets, though not all pack sizes may be marketed in every country.

Frequently Asked Questions About Ibetin